🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 17 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 11/05/2000 | 33,50 | 34,63 | 33,00 | 34,63 | +7,76% | 4,85% | 1.221.800 |
| 10/05/2000 | 31,94 | 33,31 | 28,44 | 32,13 | +1,31% | 15,26% | 1.361.400 |
| 09/05/2000 | 35,69 | 36,69 | 30,59 | 31,72 | -2,50% | 17,08% | 4.565.800 |
| 08/05/2000 | 29,75 | 33,25 | 29,75 | 32,53 | +7,32% | 11,76% | 908.000 |
| 05/05/2000 | 27,88 | 30,69 | 27,56 | 30,31 | +7,30% | 11,21% | 619.600 |
| 04/05/2000 | 26,25 | 28,69 | 26,25 | 28,25 | +5,12% | 9,29% | 514.200 |
| 03/05/2000 | 28,13 | 28,25 | 25,38 | 26,88 | -6,11% | 10,22% | 615.000 |
| 02/05/2000 | 27,38 | 29,13 | 27,06 | 28,63 | +3,39% | 7,53% | 1.089.000 |
| 01/05/2000 | 26,31 | 29,19 | 26,00 | 27,69 | +5,98% | 12,11% | 800.400 |
| 28/04/2000 | 24,38 | 26,94 | 24,13 | 26,13 | +8,57% | 11,54% | 596.000 |
| 27/04/2000 | 22,69 | 24,06 | 22,50 | 24,06 | +4,05% | 6,89% | 167.000 |
| 26/04/2000 | 25,38 | 25,50 | 23,00 | 23,13 | -7,50% | 9,85% | 291.600 |
| 25/04/2000 | 22,70 | 25,50 | 22,53 | 25,00 | +9,89% | 13,08% | 703.600 |
| 24/04/2000 | 23,06 | 24,25 | 21,25 | 22,75 | -2,80% | 13,01% | 438.200 |
| 20/04/2000 | 27,59 | 27,59 | 23,00 | 23,41 | -7,87% | 16,65% | 852.000 |
| 19/04/2000 | 25,38 | 26,31 | 24,81 | 25,41 | +0,62% | 5,91% | 712.800 |
| 18/04/2000 | 21,09 | 25,38 | 21,06 | 25,25 | +16,09% | 20,44% | 566.200 |
| 17/04/2000 | 18,89 | 21,75 | 18,88 | 21,75 | +10,48% | 15,22% | 817.800 |
| 14/04/2000 | 21,63 | 22,13 | 19,00 | 19,69 | -8,96% | 14,45% | 410.200 |
| 13/04/2000 | 22,03 | 23,38 | 21,63 | 21,63 | -1,14% | 7,94% | 170.400 |
| 12/04/2000 | 22,84 | 24,00 | 21,88 | 21,88 | -3,58% | 9,30% | 423.800 |
| 11/04/2000 | 23,50 | 23,50 | 21,25 | 22,69 | -4,85% | 9,57% | 497.000 |
| 10/04/2000 | 27,50 | 27,50 | 23,69 | 23,84 | -12,20% | 13,86% | 350.000 |
| 07/04/2000 | 27,75 | 27,81 | 26,08 | 27,16 | -2,25% | 6,25% | 611.400 |
| 06/04/2000 | 25,19 | 27,80 | 25,19 | 27,78 | +13,97% | 10,36% | 1.048.800 |
| 05/04/2000 | 20,75 | 24,81 | 20,75 | 24,38 | +13,70% | 19,58% | 1.637.200 |
| 04/04/2000 | 23,03 | 23,25 | 19,75 | 21,44 | -6,03% | 15,20% | 945.800 |
| 03/04/2000 | 23,97 | 24,00 | 22,44 | 22,81 | -2,54% | 6,52% | 824.400 |
| 31/03/2000 | 24,25 | 24,78 | 21,34 | 23,41 | -2,47% | 14,18% | 1.579.000 |
| 30/03/2000 | 26,25 | 26,34 | 23,16 | 24,00 | -8,02% | 12,14% | 892.600 |